Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Addex Therapeutics has announced positive preclinical data from studies of GABA-B receptor (GABA-BR) positive allosteric modulator (PAM) oral small molecule in overactive bladder (OAB).
Subscribe to our email newsletter
The ADX71441 compound, analyzed in female guinea pigs with bladder overactivity, induced an increase in inter contraction interval, a validated measure of bladder muscle control, in the first 15 minutes post-administration compared to vehicle.
The efficacy of ADX71441 was well correlated with its pharmacokinetic properties and also decreased micturition (urination) frequency compared to vehicle at the 1mg/kg dose, the company said.
In an independent mouse diuretic stress-induced model of overactive bladder, administration of ADX71441 dose-dependently normalized urination latencies and also dose-dependently reduced micturition frequency in furosemide-treated animals.
The magnitude of the effect in response to 10mg/kg ADX71441 was similar to those observed in oxybutynin treated animals.
Addex president and CEO Bharatt Chowrira said: "These data along with our recent announcement of positive phase 2 data in Parkinson’s disease levodopa-induced dyskinesia demonstrate the strength of our pipeline based on allosteric modulator oral small molecule platform and its ability to generate multiple high value novel product opportunities."